Gaëlle Fromont

Dr. Gaëlle Fromont


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in Human Pathology
Verified
Journal Article
Closed access
SFSandy Figiel
Sandy Figiel
CVCaroline Vasseur
Caroline Vasseur
FBFranck Bruyere
Franck Bruyere
FRFrancois Rozet
Francois Rozet
KMKarine Maheo
Karine Maheo
GFGaëlle Fromont
Gaëlle Fromont

Verified
Journal Article
Open access
PDF file
MCmathilde cancel
mathilde cancel
WPWilliam Pouillot
William Pouillot
KMKarine Mahéo
Karine Mahéo
AFAlix Fontaine
Alix Fontaine
David CrottesDavid Crottes
David Crottes
GFGaëlle Fromont
Gaëlle Fromont
Adipose tissue is part of the prostate cancer (PCa) microenvironment not only in the periprostatic area, but also in the most frequent metastatic sites, such as bone marrow and pelvic lymph nodes. The involvement of periprostatic adipose tissue (PPAT) in the aggressiveness of PCa is strongly suggested by numerous studies. Many molecules play a role in the reciprocal interaction between adipocytes and PCa cells, including adipokines, hormones, lipids, and also lipophilic pollutants stored in adipocytes. The crosstalk has consequences not only on cancer cell growth and metastatic potential, but also on adipocytes. Although most of the molecules released by PPAT are likely to promote tumor growth and the migration of cancer cells, others, such as the adipokine adiponectin and the n-6 or n-3 polyunsaturated fatty acids (PUFAs), have been shown to have anti-tumor properties. The effects of PPAT on PCa cells might therefore depend on the balance between the pro- and anti-tumor components of PPAT. In addition, genetic and environmental factors involved in the risk and/or aggressiveness of PCa, including obesity and diet, are able to modulate the interactions between PPAT and cancer cells and their consequences on the growth and the metastatic potential of PCa.

8 July 2019 in Cancers
Verified
Journal Article
Open access
PDF file
MBMichela Bernardini
Michela Bernardini
ABAlessia Brossa
Alessia Brossa
Giorgia ChinigòGiorgia Chinigò
Giorgia Chinigò
GGGrolez Guillaume
Grolez Guillaume
GTGiulia Trimaglio
Giulia Trimaglio
Dimitra GkikaDimitra Gkika
Dimitra Gkika
Background: Transient receptor potential (TRP) channels control multiple processes involved in cancer progression by modulating cell proliferation, survival, invasion and intravasation, as well as, endothelial cell (EC) biology and tumor angiogenesis. Nonetheless, a complete TRP expression signature in tumor vessels, including in prostate cancer (PCa), is still lacking. Methods: In the present study, we profiled by qPCR the expression of all TRP channels in human prostate tumor-derived ECs (TECs) in comparison with TECs from breast and renal tumors. We further functionally characterized the role of the ‘prostate-associated’ channels in proliferation, sprout formation and elongation, directed motility guiding, as well as in vitro and in vivo morphogenesis and angiogenesis. Results: We identified three ‘prostate-associated’ genes whose expression is upregulated in prostate TECs: TRPV2 as a positive modulator of TEC proliferation, TRPC3 as an endothelial PCa cell attraction factor and TRPA1 as a critical TEC angiogenic factor in vitro and in vivo. Conclusions: We provide here the full TRP signature of PCa vascularization among which three play a profound effect on EC biology. These results contribute to explain the aggressive phenotype previously observed in PTEC and provide new putative therapeutic targets.

1 March 2018 in European Journal of Cancer
Verified
Journal Article
Closed access
SFSandy Figiel
Sandy Figiel
MPMichelle Pinault
Michelle Pinault
IDIsabelle Domingo
Isabelle Domingo
CGCyrille Guimaraes
Cyrille Guimaraes
RGRoseline Guibon
Roseline Guibon
GFGaëlle Fromont
Gaëlle Fromont

29 December 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AGAnis Gasmi
Anis Gasmi
GRGuilhem Roubaud
Guilhem Roubaud
CDCharles Dariane
Charles Dariane
EBEric Barret
Eric Barret
JBJean-Baptiste Beauval
Jean-Baptiste Beauval
RMRomain Mathieu
Romain Mathieu
Deregulation of the PI3K-Akt-mTOR pathway plays a critical role in the development and progression of many cancers. In prostate cancer, evidence suggests that it is mainly driven by PTEN loss of function. For many years, the development of selective Akt inhibitors has been challenging. In recent phase II and III clinical trials, Ipatasertib and Capivasertib associated with androgen deprivation therapies showed promising outcomes in patients with metastatic castration-resistant prostate cancer and PTEN-loss. Ongoing trials are currently assessing several Akt inhibitors in prostate cancer with different combinations, at different stages of the disease.

Verified
Journal Article
Open access
PDF file
FBFanny Bery
Fanny Bery
SFSandy Figiel
Sandy Figiel
SKSana Kouba
Sana Kouba
DFDelphine Fontaine
Delphine Fontaine
Maxime F. GuéguinouMaxime F. Guéguinou
Maxime F. Guéguinou
KMKarine Mahéo
Karine Mahéo
Hypoxia is a well-established feature of prostate cancer (PCa) and is associated with disease aggressiveness. The hypoxic microenvironment initiates multiple adaptive responses including epithelial-to-mesenchymal transition (EMT) and a remodeling of calcium homeostasis involved in cancer progression. In the present study, we identified a new hypoxia signaling pathway with a positive feedback loop between the EMT transcription factor Zeb1 and SK3, a Ca2+-activated K+ channel, which leads to amplifying store-operated Ca2+ entry. Zeb1 and SK3 channel were strongly upregulated by hypoxia both in vitro and ex vivo in organotypic cultures of human PCa. Taking into account the sensitivity of the SK3 channel to the membrane lipid composition, we identified lipids such as Ohmline (an alkyl ether lipid and SK3 inhibitor), linoleic acid (LA) and eicosapentaenoic acid (EPA) (fatty acids associated with indolent PCa), which were able to completely abrogate the hypoxia-induced changes in Zeb1 expression. Ultimately, better understanding of this new hypoxia-induced EMT pathway may allow to develop adjuvant therapeutic strategies, in order to control PCa aggressiveness and improve treatment outcomes.